AngioDynamics Completes Enrollment For PRESERVE Clinical Study
Portfolio Pulse from Happy Mohamed
AngioDynamics, Inc. (NASDAQ:ANGO) has completed enrollment and final treatment in its PRESERVE study, a pivotal study of the NanoKnife System for Ablation of Prostate Tissue in an Intermediate-Risk Patient Population. The study was initiated in partnership with the Society of Urologic Oncology Clinical Trials Consortium. The PRESERVE study aims to demonstrate the NanoKnife System's ability to expand treatment options for patients with intermediate-risk prostate cancer.
August 04, 2023 | 1:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The completion of enrollment and final treatment in the PRESERVE study could potentially boost AngioDynamics' reputation in the medical technology industry. The success of the study could lead to increased adoption of the NanoKnife System, potentially driving up the company's stock price.
The completion of the PRESERVE study is a significant milestone for AngioDynamics. If the study results are positive, it could lead to increased adoption of the NanoKnife System, which would likely drive up demand for the company's products and potentially its stock price. However, the actual impact will depend on the study results, which are not yet available.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100